Thrombotic complications in adult patients with lymphoma: A meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events

Blood

Volumn 115, Issue 26, 2010, Pages 5322-5328

  Caruso, Vanesa ^a   Di Castelnuovo, Augusto ^b   Meschengieser, Susana ^a   Lazzari, Maria A ^a   De Gaetano, Giovanni ^b   Storti, Sergio ^b   Iacoviello, Licia ^b   Donati, Maria Benedetta ^b  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; CANCER PATIENT; COCHRANE LIBRARY; COHORT ANALYSIS; EMBASE; HODGKIN DISEASE; HUMAN; HYPERCOAGULABILITY; LYMPHOMA; MEDLINE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; THROMBOSIS; VEIN THROMBOSIS; META ANALYSIS; RISK;

ADULT; COHORT STUDIES; HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; RISK; THROMBOSIS;

EID: 77955869841     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-258624     Document Type: Article

References (87)

1. Falanga A, Donati MB. Pathogenesis of thrombosis in patients with malignancy. Int J Hematol. 2001;73(2):137-144.
2. Donati MB. Thrombosis and cancer: a personal view. Thromb Haemost. 2007;98(1):126-128.
3. Korte W. Cancer and thrombosis: an increasingly important association. Support Care Cancer. 2008;16(3):223-228.
4. Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4(3):529-535.
5. White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med. 2005;165(15):1782-1787. (Pubitemid 41138968)
6. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24(3):484-490.
7. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Donati MB. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost. 2007;5(3):621-623.
8. Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 paediatric patients. Blood. 2006;108(7):2216-2222. (Pubitemid 44497502)
9. Kwaan HC, Vicuna B. Incidence and pathogenesis of thrombosis in hematologic malignancies. Semin Thromb Hemost. 2007;33(4):303-312.
10. Kwaan HC, Vicuna B. Thrombosis and bleeding in cancer patients. Oncol Rev. 2007;1(1):14-27.
11. Chong BH, Lee SH. Management of thromboembolism in hematologic malignancies. Semin Thromb Hemost. 2007;33(4):435-448.
12. Linenberger ML, Wittkowsky AK. Thromboembolic complications of malignancy. Part 1: risks. Oncology (Williston Park). 2005;19(7):853-861.
13. Rosovsky RP, Kuter DJ. Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management. Hematol Oncol Clin North Am. 2005;19(1):183-202. (Pubitemid 40522270)
14. Wada H, Sase T, Yamaguchi M. Hypercoagulant states in malignant lymphoma. Exp Oncol. 2005;27(3):179-185.
15. Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol. 2003;72(1):43-52.
16. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol. 2001;106(1-2):6-12.
17. Monreal M, Davant E. Thrombotic complications of central venous catheters in cancer patients. Acta Haematol. 2001;106(1-2):69-72.
18. Otten HM, Prins MH, Smorenburg SM, Hutten BA. Risk assessment and prophylaxis of venous thromboembolism in non-surgical patients: cancer as a risk factor. Haemostasis. 2000;30(suppl 2):72-76.
19. Barbui T, Finazzi G, Grassi A, Marchioli R. Thrombosis in cancer patients treated with hematopoietic growth factors - a meta-analysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1996;75(2):368-371. (Pubitemid 26081498)
20. Piccioli A, Vianello F, Prandoni P. Management of thrombosis in patients with hematologic malignancies. Curr Hematol Rep. 2002;1(1):79-83.
21. Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 2003;8(4):381-388.
22. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-634.
23. Betticher DC, Martinelli G, Radford JA, et al. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol. 2006;17(10):1546-1552.
24. Kamikura Y, Wada H, Sase T, et al. Hemostatic abnormalities and leukocyte activation caused by infection in patients with malignant lymphoma during chemotherapy. Thromb Res. 2006;117(6):671-679.
25. Monreal M, Munoz FJ, Rosa V, et al. Upper extremity DVT in oncological patients: analysis of risk factors. Data from the RIETE registry. Exp Oncol. 2006;28(3):245-247. (Pubitemid 44735918)
26. De Lucia D, De Francesco F, Marotta R, et al. Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma. Exp Oncol. 2005;27(2):159-161.
27. Sase T, Wada H, Yamaguchi M, et al. Haemostatic abnormalities and thrombotic disorders in malignant lymphoma. Thromb Haemost. 2005;93(1):153-159.
28. Bernstein R, Haim N, Brenner B, Sarig G, Bar-Sela G, Gaitini D. Venous sonography for the diagnosis of asymptomatic deep vein thrombosis in patients with cancer undergoing chemotherapy. J Ultrasound Med. 2004;23(5):655-658. (Pubitemid 38580585)
29. Di Micco P, Niglio A, De Renzo A, et al. Congenital and acquired thrombotic risk factors in lymphoma patients bearing upper extremities deep venous thrombosis: a preliminary report. J Transl Med. 2004;2(1):7.
30. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715-722. (Pubitemid 40216041)
31. Bairey O, Gabbay U, Blickstein D, et al. Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients. Hematol Oncol. 1997;15(3):121-127.
32. Zuckerman E, Toubi E, Golan TD, et al. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer. 1995;72(2):447-451.
33. Conlan MG, Haire WD, Kessinger A, Armitage JO. Prothrombotic hemostatic abnormalities in patients with refractory malignant lymphoma presenting for autologous stem cell transplantation. Bone Marrow Transplant. 1991;7(6):475-479.
34. Zurborn KH, Duscha H, Gram J, Bruhn HD. Investigations of coagulation system and fibrinolysis in patients with disseminated adenocarcinomas and non-Hodgkin's lymphomas. Oncology. 1990;47(5):376-380. (Pubitemid 20270165)
35. Fagnani D, Franchi R, Porta C, et al; POLONORD Group. Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis. Ann Oncol. 2007;18(3):551-555.
36. Kröger K, Weiland D, Ose C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 2006;17(2):297-303.
37. Miesbach W, Scharrer I, Asherson R. Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies. Clin Rheumatol. 2006;25(6):840-844. (Pubitemid 44473149)
38. Cortelezzi A, Moia M, Falanga A, et al; CATHEM Study Group. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol. 2005;129(6):811-817.
39. Mohren M, Markmann I, Dworschak U, et al. Thromboembolic complications after splenectomy for hematologic diseases. Am J Hematol. 2004;76(2):143-147. (Pubitemid 38702558)
40. van Rooden CJ, Rosendaal FR, Barge RM, et al. Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler-ultrasound. Br J Haematol. 2003;123(3):507-512.
41. Cortelezzia A, Fracchiolla NS, Maisonneuve P, et al. Central venous catheter-related complications in patients with hematological malignancies: a retrospective analysis of risk factors and prophylactic measures. Leuk Lymphoma. 2003;44(9):1495-1501.
42. Fijnheer R, Paijmans B, Verdonck LF, Nieuwenhuis HK, Roest M, Dekker AW. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol. 2002;118(1):267-270.
43. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002;87(4):575-579. (Pubitemid 34302943)
44. Komrokji RS, Uppal NP, Khorana AA, et al. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006;47(6):1029- 1033.
45. Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 2002;87(6):1076-1077.
46. Seifter EJ, Parker RI, Gralnick HR, et al. Abnormal coagulation results in patients with Hodgkin's disease. Am J Med. 1985;78(6 Pt 1):942-950.
47. Caocci G, Fenu L, La Nasa G, Marongiu F. Superior sagittal sinus thrombosis after lumbar puncture in a patient with T-cell lymphoblastic lymphoma: role of the prothrombin G20210A mutation and 4G/4G genotype. Thromb Haemost. 2005;94(4):881-882. (Pubitemid 41489254)
48. Imamura T, Morimoto A, Kato R, et al. Cerebral thrombotic complications in adolescent leukemia/lymphoma patients treated with L-asparaginase-containing chemotherapy. Leuk Lymphoma. 2005;46(5):729-735.
49. Shaw BE, Perry D, Hoffbrand AV. Progressive arterial thrombosis in a patient with non-Hodgkin's lymphoma, a lupus anticoagulant, factor V Leiden mutation and paraprotein, following chemotherapy. Leuk Lymphoma. 2001;42(1-2):221-223.
50. Genvresse I, Buttgereit F, Späth-Schwalbe E, Ziemer S, Eucker J, Possinger K. Arterial thrombosis associated with anticardiolipin and anti-beta2-glycoprotein-I antibodies in patients with non-Hodgkin's lymphoma: a report of two cases. Eur J Haematol. 2000;65(5):344-347.
51. Keung YK, Cobos E, Meyerrose GE, Roberson GH. Progressive thrombosis after treatment of diffuse large cell non-Hodgkin's lymphoma and concomitant lupus anticoagulant. Leuk Lymphoma. 1996;20(3-4):341-345. (Pubitemid 126714891)
52. Scholz KH, Herrmann C, Tebbe U, Chemnitius JM, Helmchen U, Kreuzer H. Myocardial infarction in young patients with Hodgkin's disease - potential pathogenic role of radiotherapy, chemotherapy, and splenectomy. Clin Invest. 1993;71(1):57-64.
53. Adelstein DJ, Hines JD, Carter SG, Sacco D. Thromboembolic events in patients with malignant superior vena cava syndrome and the role of anticoagulation. Cancer. 1988;62(10):2258-2262.
54. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846-1850.
55. Baron JA, Gridley G, Weiderpass E, Nyrén O, Linet M. Venous thromboembolism and cancer. Lancet. 1998;351(9109):1077-1080.
56. Haire WD. Antithrombin deficiency in special clinical syndromes - Part II: hematologic malignancies and bone marrow transplantation. Semin Hematol. 1995;32(suppl 2):56-60. (Pubitemid 26030785)
57. Catani L, Gugliotta L, Mattioli Belmonte M, et al. Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies. Bone Marrow Transplant. 1993;12(3):253-259.
58. Conlan MG, Haire WD, Lieberman RP, Lund G, Kessinger A, Armitage JO. Catheter-related thrombosis in patients with refractory lymphoma undergoing autologous stem cell transplantation. Bone Marrow Transplant. 1991;7(3):235-240.
59. Komrokji RS, Uppal NP, Khorana AA, et al. Venous thromboembolic events in patients with diffuse large B cell non-Hodgkin's lymphoma [abstract]. Blood. 2004;104: Abstract 4542.
60. Goldschmidt N, Linetsky E, Shalom E, Varon D, Siegal T. High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer. 2003;98(6):1239-1242. (Pubitemid 37099909)
61. Clarke CS, Otridge BW, Carney DN. Thromboembolism. A complication of weekly chemotherapy in the treatment of non-Hodgkin's lymphoma. Cancer. 1990;66(9):2027-2030.
62. Cantwell BM, Carmichael J, Ghani SE, Harris AL. Thromboses and thromboemboli in patients with lymphoma during cytotoxic chemotherapy. BMJ. 1988;297(6642):179-180.
63. Seifter EJ, Young RC, Longo DL. Deep venous thrombosis during therapy for Hodgkin's disease. Cancer Treat Rep. 1985;69(9):1011-1013.
64. Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A. Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis. Br J Cancer. 2005;92(8):1349-1351.
65. Glenn LD, Armitage JO, Goldsmith JC, Sorensen S, Howe D, Weisenberger DD. Pulmonary emboli in patients receiving chemotherapy for non-Hodgkin's lymphoma. Chest. 1988;94(3):589-594.
66. Nand S, Fisher SG, Salgia R, Fisher RI. Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol. 1987;5(12):1998-2003.
67. Otten HM, Mathijssen J, ten Cate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med. 2004 Jan 26;164(2):190-194. (Pubitemid 38140406)
68. Genvresse I, Lüftner D, Späth-Schwalbe E, Buttgereit F. Prevalence and clinical significance of anticardiolipin and anti-beta2- glycoprotein-I antibodies in patients with non-Hodgkin's lymphoma. Eur J Haematol. 2002;68(2):84-90.
69. Khorana AA, FrancisCW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104(12):2822-2829.
70. Pusterla S, Previtali S, Marziali S, et al. Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. Hematol J. 2004;5(4):341-346. (Pubitemid 39214212)
71. Stasi R, Stipa E, Masi M, et al. Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma. Thromb Haemost. 1993;70(4):568-572.
72. Milne A, Talbot S, Bevan D. Thromboses during cytotoxic chemotherapy. BMJ. 1988;297(6648):624.
73. Ottinger H, Belka C, Kozole G, et al. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol. 1995;54(3):186-194.
74. Ratcliffe M, Broadfoot C, Davidson M, Kelly KF, Greaves M. Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease. Clin Lab Haematol. 1999;21(5):353-357.
75. Sletnes KE, Holte H, Halvorsen S, Jakobsen E, Wisløff F, Kvaløy S. Activation of coagulation and deep vein thrombosis after bone marrow harvesting and insertion of a Hickman-catheter in ABMT patients with malignant lymphoma. Bone Marrow Transplant. 1996;17(4):577-581.
76. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285-291. (Pubitemid 29439263)
77. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006;119(1):60-68. (Pubitemid 43117468)
78. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458-464.
79. Khorana AA, FrancisCW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339-2346.
80. Martin DO, Austin H. Exact estimates for a rate ratio. Epidemiology. 1996;7(1):29-33.
81. Monreal M. Screening for occult cancer in patients with acute venous thromboembolism. J Thromb Haemost. 2005;3(11):2389-2390. (Pubitemid 41727151)
82. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(suppl 1):17-21.
83. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907.
84. Sørensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338(17):1169-1173.
85. Donati MB, Falanga A, Lorenzet R. Cancer and thrombosis: a two way interaction. In: Arnout J, de Gaetano G, Hoylaerts M, Peerlinck K, Van Geet C, Verhaeghe R, eds. Thrombosis. Fundamental and Clinical Aspects. Leuven: University Press; 2003:417-431.
86. Gómez-Puerta JA, Cervera R, Espinosa G, et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum. 2006;35(5):322-332.
87. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490-5505. (Pubitemid 350232226)